Published in Ann Surg Oncol on May 23, 2014
Multimodality treatment strategies have changed prognosis of peritoneal metastases. World J Gastrointest Oncol (2016) 0.79
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: survival outcomes and patient selection. J Gastrointest Oncol (2016) 0.78
Abdominal metastases from colorectal cancer: intraperitoneal therapy. J Gastrointest Oncol (2015) 0.77
Treatment of peritoneal surface malignancies with hyperthermic intraperitoneal chemotherapy-current perspectives. Curr Oncol (2016) 0.76
Therapeutic options for peritoneal metastasis arising from colorectal cancer. World J Gastrointest Pharmacol Ther (2016) 0.75
Computerized System for Staging Peritoneal Surface Malignancies. Ann Surg Oncol (2015) 0.75
Short-term outcome in patients treated with cytoreduction and HIPEC compared to conventional colon cancer surgery. Medicine (Baltimore) (2016) 0.75
Multidisciplinary Treatment for Colorectal Peritoneal Metastases: Review of the Literature. Gastroenterol Res Pract (2016) 0.75
Surveillance after curative treatment for colorectal cancer. Nat Rev Clin Oncol (2016) 0.75
Cytoreductive surgery (SRC) and hyperthermic intraperitoneal chemotherapy (HIPEC) for treatment of peritoneal carcinomatosis: Our initial experience and technical details. Ulus Cerrahi Derg (2015) 0.75
Bowel strangulation caused by massive intraperitoneal adhesion due to effective chemotherapy for multiple peritoneal metastases originating from descending colon cancer. Clin J Gastroenterol (2016) 0.75
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for peritoneal carcinomatosis from colorectal cancer: a systematic review and meta-analysis of current evidence. Oncotarget (2017) 0.75
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell (2003) 15.43
Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol (2012) 5.06
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol (2007) 4.06
Ovarian cancer. Lancet (2009) 3.95
ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res (2005) 3.44
Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci U S A (2009) 3.08
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol (2009) 3.04
Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol (2009) 2.99
Left-sided pancreatectomy: a multicenter comparison of laparoscopic and open approaches. Ann Surg (2008) 2.80
Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin Cancer Res (2010) 2.56
Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2005) 2.47
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial. Gynecol Oncol (2011) 2.35
Association between a high number of isolated lymph nodes in T1 to T4 N0M0 colorectal cancer and the microsatellite instability phenotype. Arch Surg (2010) 2.26
Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. J Clin Oncol (2007) 2.24
Therapeutic advances in pancreatic cancer. Gastroenterology (2013) 2.17
Hyperthermic intraperitoneal chemotherapy in the management of ovarian cancer: A critical need for an evidence-based evaluation. Gynecol Oncol (2009) 2.15
Sox17 regulates organ lineage segregation of ventral foregut progenitor cells. Dev Cell (2009) 2.14
Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol (2009) 2.11
Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin Cancer Res (2012) 2.04
Factors associated with clinically significant anastomotic leakage after large bowel resection: multivariate analysis of 707 patients. World J Surg (2002) 1.97
Preoperative chemoradiation in patients with resectable rectal cancer: results on tumor response. Ann Surg Oncol (2002) 1.97
Recombinant human erythropoietin as an adjunct to radiation therapy and cisplatin for stage IIB-IVA carcinoma of the cervix: a Southwest Oncology Group study. Gynecol Oncol (2004) 1.96
Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect. Ann Surg Oncol (2005) 1.96
Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol (2010) 1.95
beta-Catenin mutation is a frequent cause of Wnt pathway activation in gastric cancer. Cancer Res (2002) 1.86
Results of R0 resection for colorectal liver metastases associated with extrahepatic disease. Ann Surg Oncol (2004) 1.81
Surgery for pancreatic cancer: recent controversies and current practice. Gastroenterology (2005) 1.78
Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features. Cancer Res (2007) 1.69
Local recurrences after intraoperative radiofrequency ablation of liver metastases: a comparative study with anatomic and wedge resections. Ann Surg Oncol (2004) 1.69
Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2008) 1.69
Wnt/beta-catenin signaling is required for development of the exocrine pancreas. BMC Dev Biol (2007) 1.68
Cytoreductive surgery and intraperitoneal chemo-hyperthermia for chemo-resistant and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients. World J Surg (2007) 1.66
Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2006) 1.64
The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: a Gynecologic Oncology Group study. Gynecol Oncol (2011) 1.62
A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin N Am (2003) 1.60
Intraperitoneal therapy for stage III ovarian cancer: a therapy whose time has come! J Clin Oncol (2002) 1.56
Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol (2007) 1.56
Hysteroscopic injection of tracers in sentinel node detection of endometrial cancer: a feasibility study. Am J Obstet Gynecol (2004) 1.55
Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2009) 1.53
Peritonectomy and intraperitoneal hyperthermic perfusion (IPHP): a strategy that has confirmed its efficacy in patients with pseudomyxoma peritonei. Ann Surg Oncol (2004) 1.51
Erythromycin improves the quality of EGD in patients with acute upper GI bleeding: a randomized controlled study. Gastrointest Endosc (2002) 1.49
Sentinel lymph nodes of colorectal carcinoma: reappraisal of 123 cases. Gastroenterol Clin Biol (2007) 1.48
Factors associated with insulin and narcotic independence after islet autotransplantation in patients with severe chronic pancreatitis. J Am Coll Surg (2005) 1.48
The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression. Cancer Res (2007) 1.47
Why overall survival should not be the sole valid primary endpoint of phase 3 ovarian cancer chemotherapy trials. Gynecol Oncol (2007) 1.47
Disparities in gastric cancer outcomes among Asian ethnicities in the USA. Ann Surg Oncol (2009) 1.46
Treatment of peritoneal carcinomatosis from colorectal cancer: impact of complete cytoreductive surgery and difficulties in conducting randomized trials. Ann Surg Oncol (2004) 1.46
The Frey procedure for chronic pancreatitis secondary to pancreas divisum. JAMA Surg (2013) 1.46
Impact of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on systemic toxicity. Ann Surg Oncol (2007) 1.46
Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol (2005) 1.45
Ampullary carcinoid tumors: rationale for an aggressive surgical approach. J Gastrointest Surg (2003) 1.45
Cytoreductive surgery with intraperitoneal chemohyperthermia for the treatment of pseudomyxoma peritonei: a prospective study. Dis Colon Rectum (2005) 1.44
Peritoneal carcinomatosis: cytoreductive surgery and HIPEC--overview and basics. Cancer Invest (2012) 1.42
The use of adjuvant radiation therapy in patients with intermediate-risk Stages IC and II uterine corpus cancer: a patient care evaluation study from the American College of Surgeons National Cancer Data Base. Gynecol Oncol (2005) 1.41
Consensus statement on the loco-regional treatment of appendiceal mucinous neoplasms with peritoneal dissemination (pseudomyxoma peritonei). J Surg Oncol (2008) 1.41
Lymph node metastases in diffuse malignant peritoneal mesothelioma. Ann Surg Oncol (2009) 1.38
Refocusing the debate: evidence-based clinical cancer research versus marketplace reality. J Oncol Pract (2008) 1.38
Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol (2013) 1.36
Total pancreatectomy and autologous islet cell transplantation as a means to treat severe chronic pancreatitis. J Gastrointest Surg (2003) 1.35
Clinical cancer advances 2010: annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol (2010) 1.33
Duodenal gangliocytic paraganglioma with lymph node metastasis: a case report and review of the literature. Arch Pathol Lab Med (2003) 1.33
Silencing of RON receptor signaling promotes apoptosis and gemcitabine sensitivity in pancreatic cancers. Cancer Res (2010) 1.31
Consensus statement on the loco regional treatment of colorectal cancer with peritoneal dissemination. J Surg Oncol (2008) 1.28
Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2007) 1.28
Development of an orthotopic model of invasive pancreatic cancer in an immunocompetent murine host. Clin Cancer Res (2010) 1.27
Paclitaxel in cancer therapy. Expert Opin Pharmacother (2002) 1.26
Improved sphincter preservation in low rectal cancer with high-dose preoperative radiotherapy: the lyon R96-02 randomized trial. J Clin Oncol (2004) 1.24
Risk factors for intra-abdominal septic complications after a first ileocecal resection for Crohn's disease: a multivariate analysis in 161 consecutive patients. Dis Colon Rectum (2007) 1.22
The management of recurrent ovarian cancer. Semin Oncol (2007) 1.22
KRas induces a Src/PEAK1/ErbB2 kinase amplification loop that drives metastatic growth and therapy resistance in pancreatic cancer. Cancer Res (2012) 1.22
Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Ann Surg Oncol (2007) 1.21
The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group study. Cancer (2009) 1.18
A comparative study of complete cytoreductive surgery plus intraperitoneal chemotherapy to treat peritoneal dissemination from colon, rectum, small bowel, and nonpseudomyxoma appendix. Ann Surg (2010) 1.16
Improved results using ultrasound guidance for central venous access. Am Surg (2003) 1.15
Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia. Blood (2007) 1.14
Unfolding the pathophysiological role of bioactive lysophospholipids. Curr Drug Targets Immune Endocr Metabol Disord (2003) 1.13
Increased biliary fistulas after liver resection with the harmonic scalpel. Am Surg (2003) 1.13